We would love to hear your thoughts about our site and services, please take our survey here.
Only 1 j left at 0.85 now, now should be reached soon
Only 2500 worth left under 0.85 rest NT ,
Attack on 0.85 imminent
They are raising bid to get sells, hold your shares 1 p on its way
Tricky MMS are clever, they want sells, so they can get cheap shares and then RNS and boom all tricks
Breakthrough could happen , only need little buying pressure, oversold
0.79 to buy now, we should get breakthrough, little patience and easy 50 percent here
Couple of 2k buys and we should break 0.80 again,
Rather have sells now then over 1.50
Could be update on contacts coming
0.85 on ask now, seems could be broken as lot interest coming into Enet
0.75 now gone as nt to buy even small amounts, break 0.87 and we could see 1 today as once on riser board more attention should come to Enet
Bought in other day at 1 , now out at 1.50 GLA
Few more buys and we should see 0.80 plus
Ethernity Networks (AIM: ENET.L, OTCMKTS: ENETF), a leading supplier of networking processing semiconductor technology ported on field programmable gate arrays ("FPGA") for virtualised networking appliances, announces a business update.
In the year to date, the Company has had positive engagement with a number of potential new customers, including two OEM vendors which, following an extensive evaluation of Ethernity's Universal Edge Platform ("UEP") have indicated an interest to adopt and launch the product to their customer base and the Company is in negotiations with these two vendors on potential contracts that could lead to significant business for Ethernity. In addition, two further OEM vendors have indicated an interest to contract the Company for delivery of a UEP based design.
Based on the scopes of work being discussed with these potential new customers, should they lead to contracts, they could contribute between $2.2 million and $3 million to the Company's revenues in 2024. Given the commitment of each customer to adopt the products, this would likely lead to significantly higher revenues in 2025 and beyond. Whilst there can be no guarantee that the discussions summarised above will all lead to contracts at all or on the terms currently being discussed, the Board considers that this significant interest in the Company's products demonstrates the potential for future growth in sales of a complete system offering combining Ethernity's chip and software stack that is expected to be the main driver of the future growth of the Company.
Ethernity's products are available to OEM vendors either via the sale of complete systems or through the licencing of the Company's IP. The preferred business model is defined by the customer, depending on whether it is looking for a complete product or would like to embed Ethernity's technology within its own product, resulting in one of the two following revenue models: little updates on above will take this to 1.50
Topped up little as I see this breaking 1 p this week
We are delighted to receive this recommendation from NICE for our CYP2C19 point of care pharmacogenetic test. The NHS has done significant work on both strokes and mini strokes, with campaigns for FAST (Face, Arms, Speech, Time) and promoting changing lifestyles to prevent a stroke. This guidance is just the next step in stroke management, ensuring that if you have a stroke, specifically related to a disruption of the blood flow, that the medicine given has a positive effect. Clopidogrel is the NICE recommended front line treatment for these types of strokes. However, if you are one of the estimated 20%-30% who are unable to metabolise Clopidogrel effectively you have the opportunity to be identified quickly and given an alternative medication. We are delighted to be part of this change which is in line with our strategy to deliver point-of-care pharmacogenetic testing to positively impact patient outcomes. With MT-RNR1 getting a NICE EVA conditional recommendation last year, further funding applied for to achieve a full recommendation this year, a strategy in place to achieve Food and Drug Administration ("FDA") approval and sales being realised from new customers in 2024 we feel there is growing momentum within the Group's POC pharmacogenetic testing strategy." They may get grant from NHS
Some will buy some will sell, next RNS will tell, who got it right
Petro where is the pump? This is red
Try GDR, dropped over 50 percent days highs, alway buy on drops